Chalcones as multitarget modulators in non-small cell lung cancer: mechanistic insights and therapeutic perspectives - Top-Institutions - MDSpire

Chalcones as multitarget modulators in non-small cell lung cancer: mechanistic insights and therapeutic perspectives

  • By

  • Ellen Mayara Souza Cruz

  • Virginia Márcia Concato-Lopes

  • Mariana Barbosa Detoni

  • Manoela Daiele Gonçalves-Lens

  • Milena Cremer de Souza

  • Fabrício Seidy Ribeiro Inoue

  • Angélica Paulina Nunes

  • Elaine da Silva Siqueira

  • Ana Carolina Jacob Rodrigues

  • Yasmin Munhoz dos Santos-Destro

  • Natália Concimo Santos

  • João Manoel de Sousa Silva

  • Éder Ignácio da Silva

  • Maiara Voltarelli Providello

  • Danielle Lazarin-Bidóia

  • Fábio Rodrigues Ferreira Seiva

  • Wander Rogério Pavanelli

  • July 14, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

  • #2

    NRG Oncology
    NRG Oncology

    Philadelphia, Pennsylvania

    Key Differentiators

    • Oncology

  • #3

    Institut Gustave Roussy
    Institut Gustave Roussy

    Villejuif, France

    Key Differentiators

    • Oncology

Original Source(s)

Chalcones as multitarget modulators in non-small cell lung cancer: mechanistic insights and therapeutic perspectives

  • by Ellen Mayara Souza Cruz, Virginia Márcia Concato-Lopes, Mariana Barbosa Detoni, Manoela Daiele Gonçalves-Lens, Milena Cremer de Souza, Fabrício Seidy Ribeiro Inoue, Angélica Paulina Nunes, Elaine da Silva Siqueira, Ana Carolina Jacob Rodrigues, Yasmin Munhoz dos Santos-Destro, Natália Concimo Santos, João Manoel de Sousa Silva, Éder Ignácio da Silva, Maiara Voltarelli Providello, Danielle Lazarin-Bidóia, Fábio Rodrigues Ferreira Seiva, Wander Rogério Pavanelli

  • July 14, 2026

Related Content

Initial observations on dose optimization in 125I seed implantation for recurrent glioblastoma: safety and efficacy across low- and high-dose ranges

Transformation from lung adenocarcinoma to pulmonary giant cell carcinoma following targeted therapy: a case report

Correction: Clinical benefit and safety of immunotherapy beyond progression in advanced and locally advanced lung cancer: a real-world cohort study